Alex is the Chief Operating Officer of Remedium Bio, a Boston-area biotechnology company. Prior to Remedium Alex held roles of increasing responsibilities at companies including Allergan, Biogen, and Regeneron. His efforts were instrumental in bringing to market a number of global blockbuster therapies for the treatment of Multiple Sclerosis, Rheumatoid Arthritis, and Atopic Dermatitis. Alex holds a Bachelor in Materials Engineering and a Master in Chemical Engineering from the University of Toronto, MBA and Master of Science in Finance from Indiana University, and a Master in Microbiology and Cell Sciences from the University of Florida.
Title : rhFGF18 and rhGDF11 for the treatment of ischemic stroke